Drug Profile
SPS 4251
Alternative Names: PAP-1; SPS-4251Latest Information Update: 29 Jun 2023
Price :
$50
*
At a glance
- Originator Airmid
- Developer NIOX
- Class Antipsoriatics
- Mechanism of Action Immunosuppressants; Kv1.3 potassium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atopic dermatitis; Plaque psoriasis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Plaque-psoriasis in Germany (Topical, Ointment)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Atopic-dermatitis in United Kingdom (Topical, Ointment)
- 16 Jul 2013 Circassia completes a phase Ib trial in Plaque psoriasis in Germany (NCT01743118)